CTCL patients demonstrate increased IL-18 plasma levels and increased IL-18 mRNA levels in skin lesions, more likely induced after NLRP3 inflammasome activation, given the concomitant increase in caspase-1 mRNA in the affected skin. This evidence concerns the gene NLRP3 and primary cutaneous T-cell non-Hodgkin lymphoma.